Novo Nordisk (NVO) Stock Declines Despite Increased Sales Forecast

Novo Nordisk (NVO) raised its full-year guidance, now expecting adjusted sales and operating profit to be down 6% to flat at constant exchange rates, an improvement from a previous decline expectation of 4% to 12%. Despite a quarterly earnings beat, shares fell 3.4% during the trading session and 6% in after-hours trading. Analysts highlighted that the positive results were driven by temporary factors and expressed concerns over competition from Eli Lilly. The outlook is crucial for investors as Novo attempts to regain confidence in its long-term growth amidst strong competitor pressure.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.